Prelude Therapeutics Inc
PRLD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001678660
No open-market purchases or sales by Prelude Therapeutics Inc insiders were filed in the last 90 days; 75 institutions reported holding it in 13F filings for Q2 2026, worth $264.3M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Prelude Therapeutics Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Prelude Therapeutics Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Baker Julian | Director, 10% Owner | – | Jun 10, 2026 | 2 |
| Baker Felix | Director, 10% Owner | – | Jun 10, 2026 | 2 |
| Baker Bros. Advisors LP | Director, 10% Owner | – | Jun 10, 2026 | 2 |
| Baker Brothers Life Sciences LP | Director, 10% Owner | – | Jun 10, 2026 | 2 |
| 667, L.P. | Director, 10% Owner | – | Jun 10, 2026 | 2 |
| Baker Bros. Advisors (GP) LLC | Director, 10% Owner | – | Jun 10, 2026 | 2 |
| Friedman Paul A | Director | – | Jun 10, 2026 | 1 |
| Babler Martin | Director | – | Jun 10, 2026 | 1 |
| Bonita David P | Director, 10% Owner | 1,126,126Indirect | Jun 10, 2026 | 2 |
| Dorton Katina | Director | – | Jun 10, 2026 | 2 |
| Sandor Victor | Director | – | Jun 10, 2026 | 2 |
| Morris Charles Q | Chief Medical Officer | – | May 4, 2026 | 1 |
| RA Capital Healthcare Fund LP | 10% Owner | 6,475,882Indirect | Apr 28, 2026 | 1 |
| Ra Capital Management, L.P. | 10% Owner | 6,475,882Indirect | Apr 28, 2026 | 1 |
| Kolchinsky Peter | 10% Owner | 6,475,882Indirect | Apr 28, 2026 | 1 |
| Shah Rajeev M. | 10% Owner | 6,475,882Indirect | Apr 28, 2026 | 1 |
| OrbiMed Advisors LLC | Director, 10% Owner | 1,126,126Indirect | Apr 23, 2026 | 1 |
| OrbiMed Capital LLC | Director, 10% Owner | 1,126,126Indirect | Apr 23, 2026 | 1 |
| OrbiMed Capital GP VI LLC | Director, 10% Owner | 1,126,126Indirect | Apr 23, 2026 | 1 |
| OrbiMed Genesis GP LLC | Director, 10% Owner | 1,126,126Indirect | Apr 23, 2026 | 1 |
| Lim Bryant David | CLO, CFO, Corp Sec. | 27,400 | Feb 5, 2026 | 1 |
| Scherle Peggy | Chief Scientific Officer | 172,920 | Feb 5, 2026 | 1 |
| Vaddi Krishna | CEO | 1,999,296 | Feb 5, 2026 | 1 |
| Combs Andrew | Chief Chemistry Officer | 480,123 | Feb 5, 2026 | 1 |
| Huang Jane | President, CMO | 86,917 | Oct 7, 2025 | 1 |
| Dier Mardi | Director | – | Jun 13, 2025 | 0 |
| Chardonnet Laurent | Chief Financial Officer | 42,165 | Mar 4, 2024 | 0 |
| Morosini Deborah | EVP, Chief of Clinical Affairs | 444 | Feb 17, 2022 | 0 |
| Mauro David J | Chief Medical Officer | 0 | Oct 6, 2021 | 0 |
| Pierce Christopher | EVP and Chief of Business Oper | 3,750 | Sep 7, 2021 | 0 |
| Piper Brian | Chief Financial Officer | 0 | Aug 27, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 8, 2021 (view filing) | Jul 6 | 2 days | Mauro David JChief Medical Officer | SSale | −15.0K | $27.48 | −$412.1K | −100.0%0 after | 3 lots |
| Jul 29, 2021 (view filing) | Jul 27 | 2 days | Scherle PeggyChief Scientific Officer | SSale | −20.0K | $35.47 | −$709.4K | −10.4%172.9K after | 2 lots |
| Aug 9, 2021 (view filing) | Aug 5 | 4 days | Mauro David JChief Medical Officer | SSale | −15.0K | $31.09 | −$466.4K | −100.0%0 after | 4 lots |
| Aug 17, 2021 (view filing) | Aug 13 | 4 days | Scherle PeggyChief Scientific Officer | SSale | −2.29K | $35.07 | −$80.2K | −1.3%172.9K after | |
| Aug 27, 2021 (view filing) | Aug 25 | 2 days | Piper BrianChief Financial Officer | SSale | −8.33K | $33.34 | −$277.8K | −100.0%0 after | 3 lots |
| Aug 30, 2021 (view filing) | Aug 26-27 | 4 days | Scherle PeggyChief Scientific Officer | SSale | −7.71K | $35.75 | −$275.8K | −4.3%172.9K after | 4 lots |
| Sep 7, 2021 (view filing) | Sep 2 | 5 days | Pierce ChristopherEVP and Chief of Business Oper | SSale | −17.0K | $41.68 | −$708.5K | −81.9%3.75K after | 3 lots |
| Sep 9, 2021 (view filing) | Sep 7 | 2 days | Mauro David JChief Medical Officer | SSale | −15.0K | $36.68 | −$550.3K | −100.0%0 after | 3 lots |
| Oct 6, 2021 (view filing) | Oct 5 | 1 day | Mauro David JChief Medical Officer | SSale | −15.0K | $30.96 | −$464.3K | −100.0%0 after | 3 lots |
| Nov 18, 2021 (view filing) | Nov 16 | 2 days | Morosini DeborahEVP, Chief of Clinical Affairs | SSale | −28.8K | $15.88 | −$456.5K | −98.5%444 after | 2 lots |
| Dec 15, 2021 (view filing) | Dec 13-14 | 2 days | Combs AndrewEVP, Head of Chemistry | PPurchase | +8.00K | $11.86 | +$94.9K | +3.1%268.4K after | 2 lots |
| Dec 17, 2021 (view filing) | Dec 15 | 2 days | Morosini DeborahEVP, Chief of Clinical Affairs | SSale | −28.8K | $13.00 | −$373.8K | −98.5%444 after | |
| Jun 1, 2022 (view filing) | Jun 1 | Same day | Chardonnet LaurentChief Financial Officer | PPurchase | +10.0K | $4.23 | +$42.3K | +69.0%24.5K after | |
| Dec 12, 2022 (view filing) | Dec 8 | 4 days | Chardonnet LaurentChief Financial Officer | PPurchase | +10.0K | $4.76 | +$47.6K | +38.7%35.9K after | |
| Dec 21, 2022 (view filing) | Dec 20 | 1 day | Vaddi KrishnaCEO | PPurchase | +19.2K | $5.13 | +$98.4K | +18.9%120.7K after | |
| Apr 6, 2023 (view filing) | Apr 6 | Same day | Huang JanePresident, CMO | SSale | −13.3K | $6.12 | −$81.3K | −35.4%24.2K after | |
| May 24, 2023 (view filing) | May 22 | 2 days | Bonita David PDirector, 10% Owner | PPurchase | +869.6K | $5.75 | +$5.00M | +9.4%10.1M after | |
| May 24, 2023 (view filing)5:09 PM ET | May 22 | 2 days | OrbiMed Advisors LLC and 2 othersDirector, 10% Owner | PPurchase | +869.6K | $5.75 | +$5.00M | +9.4%10.1M after | Duplicate filing |
| May 25, 2023 (view filing) | May 23 | 2 days | Vaddi KrishnaCEO | PPurchase | +11.9K | $5.63 | +$66.7K | +1.1%1.07M after | |
| May 25, 2023 (view filing) | May 23 | 2 days | Chardonnet LaurentChief Financial Officer | PPurchase | +5.00K | $5.50 | +$27.5K | +13.5%42.2K after | |
| May 25, 2023 (view filing) | May 24 | 1 day | Lim Bryant DavidChief Legal Officer, Corp Sec. | PPurchase | +2.40K | $5.39 | +$12.9K | New position2.40K after | |
| May 26, 2023 (view filing) | May 24-25 | 2 days | Vaddi KrishnaCEO | PPurchase | +1.90K | $5.15 | +$9.79K | +0.2%1.07M after | 2 lots |
| Dec 20, 2024 (view filing) | Dec 18 | 2 days | Vaddi KrishnaCEO | PPurchase | +100.0K | $0.93 | +$93.0K | +9.4%1.17M after | |
| Dec 20, 2024 (view filing) | Dec 19 | 1 day | Vaddi KrishnaCEO | PPurchase | +6.89K | $0.89 | +$6.13K | +5.7%127.6K after | |
| Dec 20, 2024 (view filing) | Dec 19 | 1 day | Lim Bryant DavidCLO, Interim CFO, Corp Sec. | PPurchase | +25.0K | $0.91 | +$22.8K | +1,041.7%27.4K after | |
| Dec 26, 2024 (view filing) | Dec 20-23 | 6 days | Combs AndrewChief Chemistry Officer | PPurchase | +63.1K | $1.36 | +$85.7K | +20.1%377.6K after | 2 lots |
| Jan 2, 2025 (view filing) | Dec 30, 2024 | 3 days | Vaddi KrishnaCEO | PPurchase | +10.0K | $1.20 | +$12.0K | +7.8%137.6K after | |
| Jan 3, 2025 (view filing) | Dec 31, 2024 | 3 days | Vaddi KrishnaCEO | PPurchase | +5.00K | $1.21 | +$6.05K | +3.6%142.6K after | |
| Mar 14, 2025 (view filing) | Mar 12-13 | 2 days | Vaddi KrishnaCEO | PPurchase | +97.5K | $0.7151 | +$69.7K | +8.4%1.26M after | 2 lots |
| Mar 18, 2025 (view filing) | Mar 14-17 | 4 days | Vaddi KrishnaCEO | PPurchase | +39.1K | $0.75 | +$29.3K | +3.1%1.30M after | 2 lots |
| Mar 24, 2025 (view filing) | Mar 20-21 | 4 days | Vaddi KrishnaCEO | PPurchase | +20.4K | $0.73 | +$14.9K | +1.6%1.32M after | 2 lots |
| Mar 27, 2025 (view filing) | Mar 25 | 2 days | Vaddi KrishnaCEO | PPurchase | +675.0K | $0.69 | +$465.8K | +51.0%2.00M after | |
| Mar 27, 2025 (view filing) | Mar 25 | 2 days | Combs AndrewChief Chemistry Officer | PPurchase | +100.0K | $0.69 | +$69.0K | +26.3%480.1K after | |
| Apr 22, 2026 (view filing)4:15 PM ET | Apr 21 | 1 day | Baker Julian and 5 othersDirector, 10% Owner | PPurchase | +2.25M | $4.44 | +$10.0M | –20.1M after | Derivative2 lots |
| Apr 23, 2026 (view filing) | Apr 21 | 2 days | Bonita David PDirector, 10% Owner | PPurchase | +2.82M | $4.44 | +$12.5M | New position1.13M after | 2 lots |
| Apr 23, 2026 (view filing)6:48 PM ET | Apr 21 | 2 days | OrbiMed Advisors LLC and 3 othersDirector, 10% Owner | PPurchase | +2.82M | $4.44 | +$12.5M | New position1.13M after | 2 lotsDuplicate filing |